1,4-diacetoxy-2-methyl-3-(3,7,11-trimethyl-dodeca-2t,6t,10-trienyl)-naphthalene | 56298-82-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 1,4-diacetoxy-2-methyl-3-(3,7,11-trimethyl-dodeca-2t,6t,10-trienyl)-naphthalene
• 英文别名: 1,4-Diacetoxy-2-methyl-3-(3,7,11-trimethyl-dodeca-2t,6t,10-trienyl)-naphthalin；1,4-Naphthalenediol, 2-methyl-3-(3,7,11-trimethyl-2,6,10-dodecatrienyl)-, diacetate；[4-acetyloxy-2-methyl-3-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]naphthalen-1-yl] acetate
• CAS: 56298-82-9
• 化学式: C₃₀H₃₈O₄
• 分子量: 462.629
• InChiKey: LQOXSTKPVFKMOB-SEUYJHDCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.7
• 重原子数：
  34
• 可旋转键数：
  12
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  乙酸酐 、 alkaline earth salt of/the/ methylsulfuric acid 在 锌 作用下， 生成 1,4-diacetoxy-2-methyl-3-(3,7,11-trimethyl-dodeca-2t,6t,10-trienyl)-naphthalene
  参考文献：
  名称：

  Isler et al., Helvetica Chimica Acta, 1958, vol. 41, p. 786,802

  摘要：

  DOI：

文献信息

• PRODRUGS OF VITAMINE K
  申请人：KAPPA BIOSCIENCE AS

  公开号：US20150031651A1

  公开（公告）日：2015-01-29

  The invention relates to prodrugs of vitamin K2, in particular prodrugs of MK-7 in which the diketone is converted to a monosubstituted or disubstituted ester type derivative. These compounds are shown to give MK-7 in plasma.

  这项发明涉及维生素K2的前药，特别是MK-7的前药，其中二酮被转化为单取代或双取代酯类衍生物。这些化合物被证明在血浆中产生MK-7。
• COMPOSITIONS COMPRISING VITAMIN K DERIVATIVES AND SALTS
  申请人：KAPPA BIOSCIENCE AS

  公开号：US20160184254A1

  公开（公告）日：2016-06-30

  This application relates to new formulations of vitamin K1 and K2 provitamins. These formulations can be used as nutraceuticals, e.g. for the fortification of foods or simply in supplements or can be used in pharmaceuticals for the treatment of a variety of conditions known to benefit from the administration of vitamin K1 and K2.

  本申请涉及新的维生素K1和K2前维生素的配方。这些配方可以用作营养保健品，例如用于强化食品或仅仅是补充剂，也可以用于制药，治疗多种已知可从维生素K1和K2的治疗中获益的疾病。
• Prodrugs of Vitamine K
  申请人：KAPPA BIOSCIENCE AS

  公开号：US20170079994A1

  公开（公告）日：2017-03-23

  The disclosure relates to prodrugs of vitamin K2, in particular prodrugs of MK-7 in which the diketone is converted to a monosubstituted or disubstituted ester type derivative. These compounds are shown to give MK-7 in plasma. The disclosure also relates to methods of treating conditions using prodrugs of vitamin K2.
• US9512153B2
  申请人：——

  公开号：US9512153B2

  公开（公告）日：2016-12-06